OPR - Delayed Quote • USD MLYS Jun 2024 12.500 call (MLYS240621C00012500) Follow 5.0000 0.0000 (0.00%) As of April 8 at 9:32 AM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for MLYS240621C00012500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: MLYS Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ... Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024 Mineralys Therapeutics Announces $120 Million Private Placement Financing Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension Positive Signs As Multiple Insiders Buy Mineralys Therapeutics Stock Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2023 Earnings Call Transcript
